{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CR+%2B+placebo",
    "query": {
      "intervention": "CR + placebo"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 98,
    "total_pages": 10,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CR+%2B+placebo&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-28T15:49:47.171Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03587701",
      "title": "Effects of Anakinra in Subjects With Corticosteroid-resistant/Intolerant Meniere's Disease and Autoimmune Inner Ear Disease",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Autoimmune Inner Ear Disease",
        "Meniere's Disease"
      ],
      "interventions": [
        {
          "name": "Anakinra 100Mg/0.67Ml Inj Syringe (Period 1)",
          "type": "DRUG"
        },
        {
          "name": "Placebo injection (Period 1)",
          "type": "DRUG"
        },
        {
          "name": "Anakinra 100Mg/0.67Ml Inj Syringe (Period 2)",
          "type": "DRUG"
        },
        {
          "name": "Placebo injection (Period 2)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Northwell Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 57,
      "start_date": "2019-01-03",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-04-15",
      "last_synced_at": "2026-09-28T15:49:47.171Z",
      "location_count": 1,
      "location_summary": "New Hyde Park, New York",
      "locations": [
        {
          "city": "New Hyde Park",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03587701"
    },
    {
      "nct_id": "NCT03055338",
      "title": "An Active-Controlled Early Phase Study of Elpipodect (MK-8189) in Adults With Schizophrenia (MK-8189-005)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Schizophrenia, Acute Episode"
      ],
      "interventions": [
        {
          "name": "Elpipodect",
          "type": "DRUG"
        },
        {
          "name": "Risperidone",
          "type": "DRUG"
        },
        {
          "name": "Placebo matching MK-8189",
          "type": "DRUG"
        },
        {
          "name": "Placebo matching risperidone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 224,
      "start_date": "2017-03-08",
      "completion_date": "2018-01-09",
      "has_results": true,
      "last_update_posted_date": "2026-04-29",
      "last_synced_at": "2026-09-28T15:49:47.171Z",
      "location_count": 28,
      "location_summary": "Little Rock, Arkansas • Rogers, Arkansas • Bellflower, California + 23 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Rogers",
          "state": "Arkansas"
        },
        {
          "city": "Bellflower",
          "state": "California"
        },
        {
          "city": "Cerritos",
          "state": "California"
        },
        {
          "city": "Garden Grove",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03055338"
    },
    {
      "nct_id": "NCT00113295",
      "title": "Combination of Paroxetine CR and Quetiapine for the Treatment of Refractory Generalized Anxiety Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Anxiety Disorder"
      ],
      "interventions": [
        {
          "name": "Continued Paroxetine CR",
          "type": "DRUG"
        },
        {
          "name": "Quetiapine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "72 Years",
        "sex": "ALL",
        "summary": "18 Years to 72 Years"
      },
      "enrollment_count": 50,
      "start_date": "2004-02",
      "completion_date": "2007-11",
      "has_results": true,
      "last_update_posted_date": "2014-04-23",
      "last_synced_at": "2026-09-28T15:49:47.171Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts • Durham, North Carolina",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00113295"
    },
    {
      "nct_id": "NCT00110994",
      "title": "Treatment for Subjects With Unresectable Stage III or Stage IV Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cancer",
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "Sorafenib (Nexavar, BAY43-9006)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Dacarbazine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 101,
      "start_date": "2005-04",
      "completion_date": "2008-03",
      "has_results": true,
      "last_update_posted_date": "2015-06-08",
      "last_synced_at": "2026-09-28T15:49:47.171Z",
      "location_count": 14,
      "location_summary": "Tucson, Arizona • Aurora, Colorado • Lakeland, Florida + 9 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Lakeland",
          "state": "Florida"
        },
        {
          "city": "Park Ridge",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00110994"
    },
    {
      "nct_id": "NCT00814502",
      "title": "Zolpidem CR and Hospitalized Patients With Dementia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Dementia",
        "Alzheimer Disease",
        "Dementia, Vascular",
        "Sleep Disorders",
        "Circadian Dysregulation"
      ],
      "interventions": [
        {
          "name": "Zolpidem CR",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "60 Years to 99 Years"
      },
      "enrollment_count": 20,
      "start_date": "2008-12",
      "completion_date": "2013-12",
      "has_results": true,
      "last_update_posted_date": "2017-05-22",
      "last_synced_at": "2026-09-28T15:49:47.171Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00814502"
    },
    {
      "nct_id": "NCT00797966",
      "title": "Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Major Depressive Disorder"
      ],
      "interventions": [
        {
          "name": "OPC-34712",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "ADT",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 850,
      "start_date": "2009-05",
      "completion_date": "2010-07",
      "has_results": true,
      "last_update_posted_date": "2016-02-29",
      "last_synced_at": "2026-09-28T15:49:47.171Z",
      "location_count": 50,
      "location_summary": "Arcadia, California • Beverly Hills, California • Escondido, California + 43 more",
      "locations": [
        {
          "city": "Arcadia",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Escondido",
          "state": "California"
        },
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "National City",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00797966"
    },
    {
      "nct_id": "NCT05132660",
      "title": "Treating Early Stage Diabetic Retinopathy",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Diabetic Retinopathy"
      ],
      "interventions": [
        {
          "name": "Sinemet CR",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "VA Office of Research and Development",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "30 Years to 80 Years"
      },
      "enrollment_count": 244,
      "start_date": "2022-07-01",
      "completion_date": "2028-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-04-07",
      "last_synced_at": "2026-09-28T15:49:47.171Z",
      "location_count": 1,
      "location_summary": "Decatur, Georgia",
      "locations": [
        {
          "city": "Decatur",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05132660"
    },
    {
      "nct_id": "NCT00838396",
      "title": "A Study to Evaluate the Efficacy and Safety of Controlled Release Arbaclofen Placarbil (XP19986) in Patients With Gastroesophageal Reflux Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "GERD"
      ],
      "interventions": [
        {
          "name": "XP19986 CR",
          "type": "DRUG"
        },
        {
          "name": "Placebo for XP19986 CR",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Indivior Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 58,
      "start_date": "2005-10",
      "completion_date": "2006-08",
      "has_results": false,
      "last_update_posted_date": "2016-09-14",
      "last_synced_at": "2026-09-28T15:49:47.171Z",
      "location_count": 3,
      "location_summary": "Stanford, California • Charleston, South Carolina • Tacoma, Washington",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Charleston",
          "state": "South Carolina"
        },
        {
          "city": "Tacoma",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00838396"
    },
    {
      "nct_id": "NCT01689909",
      "title": "Reducing Suicidal Ideation Through Insomnia Treatment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Insomnia",
        "Depression",
        "Suicidal Ideation"
      ],
      "interventions": [
        {
          "name": "Zolpidem-CR",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Augusta University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 103,
      "start_date": "2012-12-06",
      "completion_date": "2018-01-01",
      "has_results": true,
      "last_update_posted_date": "2022-02-16",
      "last_synced_at": "2026-09-28T15:49:47.171Z",
      "location_count": 4,
      "location_summary": "Augusta, Georgia • Durham, North Carolina • Wake Forest, North Carolina + 1 more",
      "locations": [
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Wake Forest",
          "state": "North Carolina"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01689909"
    },
    {
      "nct_id": "NCT01709214",
      "title": "Safety and Efficacy Study of GRT6005 in Patients With Osteoarthritis (OA) Knee Pain",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee"
      ],
      "interventions": [
        {
          "name": "Cebranopadol (GRT6005) Low-Dose Range",
          "type": "DRUG"
        },
        {
          "name": "Cebranopadol (GRT6005) High-Dose Range",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Oxycodone CR",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tris Pharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 619,
      "start_date": "2012-12-04",
      "completion_date": "2014-04-04",
      "has_results": false,
      "last_update_posted_date": "2021-07-15",
      "last_synced_at": "2026-09-28T15:49:47.171Z",
      "location_count": 83,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 74 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01709214"
    }
  ]
}